[HTML][HTML] Novel agents and strategies for overcoming EGFR TKIs resistance
FY Niu, YL Wu - Experimental Hematology & Oncology, 2014 - Springer
Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target,
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
[HTML][HTML] Novel agents and strategies for overcoming EGFR TKIs resistance
FY Niu, YL Wu - Experimental Hematology & Oncology, 2014 - ncbi.nlm.nih.gov
Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target,
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
[PDF][PDF] Novel agents and strategies for overcoming EGFR TKIs resistance
FY Niu, YL Wu - 2014 - core.ac.uk
Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target,
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
[PDF][PDF] Novel agents and strategies for overcoming EGFR TKIs resistance
FY Niu, YL Wu - 2014 - cyberleninka.org
Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target,
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
Novel agents and strategies for overcoming EGFR TKIs resistance
FY Niu, YL Wu - Experimental Hematology & Oncology, 2014 - go.gale.com
Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer
cases [1]. The traditional treatment for NSCLC is platinum-based chemotherapy, which …
cases [1]. The traditional treatment for NSCLC is platinum-based chemotherapy, which …
Novel agents and strategies for overcoming EGFR TKIs resistance.
FY Niu, YL Wu - Experimental Hematology & Oncology, 2014 - europepmc.org
Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target,
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
[PDF][PDF] Novel agents and strategies for overcoming EGFR TKIs resistance
FY Niu, YL Wu - 2014 - Citeseer
Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target,
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
[引用][C] Novel agents and strategies for overcoming EGFR TKIs resistance
FY Niu, YL Wu - Experimental Hematology & Oncology, 2014 - cir.nii.ac.jp
Novel agents and strategies for overcoming EGFR TKIs resistance | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
[PDF][PDF] Novel agents and strategies for overcoming EGFR TKIs resistance
FY Niu, YL Wu - 2014 - scienceopen.com
Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target,
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
Novel agents and strategies for overcoming EGFR TKIs resistance
FY Niu, YL Wu - Experimental hematology & oncology, 2014 - pubmed.ncbi.nlm.nih.gov
Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target,
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …
EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR …